KalVista Pharmaceuticals

KalVista Pharmaceuticals(KALV)

FRAMINGHAM, MA
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Ophthalmology Products

KalVista Pharmaceuticals is a life sciences company focused on Ophthalmology Products.

OphthalmologyNeurology
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
0

Products & Portfolio (11)

11 discontinued products not shown

ARIPIPRAZOLE
aripiprazole
Post-LOE
SMORAL · SOLUTION
mania, is unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
Schizophrenia
2019
30
DIGOXIN
digoxin
Post-LOE
ORAL · ELIXIR
digoxin's actions are mediated through its effects on NaK–ATPase. This enzyme, the "sodium pump," is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting NaK–ATPase, digoxin causes increased availability of intracellular calcium in the myocardium and conduction system, with consequent increased inotropy, increased automaticity, and reduced conduction velocity; indirectly causes parasympathetic stimulation of the autonomic nervous system, with consequent effects on the sino-atrial (SA) and atrioventricular (AV) nodes; reduces catecholamine reuptake at nerve terminals, rendering blood vessels more sensitive to endogenous or exogenous catecholamines; increases baroreceptor sensitization, with consequent increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increment in mean arterial pressure; increases (at higher concentrations) sympathetic outflow from the central nervous system (CNS) to both cardiac and peripheral sympathetic nerves; and allows (at higher concentrations) progressive efflux of intracellular potassium, with consequent increase in serum potassium levels. The cardiologic consequences of these direct and indirect effects are an increase in the force and velocity of myocardial systolic contraction (positive inotropic action), a slowing of the heart rate (negative chronotropic effect), and decreased conduction velocity through the AV node, and a decrease in the degree of activation of the sympathetic nervous system and renin-angiotensin system (neurohormonal deactivating effect).
mild to moderate heart failureheart failureAtrial Fibrillation
2019
30
EKTERLY
sebetralstat
Launch
SMORAL · TABLET
Kallikrein Inhibitors
acute attacks of hereditary angioedema (HAE) in adultolder
2025
0
METFORMIN HYDROCHLORIDE
metformin hydrochloride
Post-LOE
ORAL · SOLUTION
2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
type 2 diabetes mellitus
2022
30
METHADONE HYDROCHLORIDE
methadone
Post-LOE
ORAL · TABLET
mu-agonist; a synthetic opioid with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The principal therapeutic uses for methadone are for analgesia and for detoxification or maintenance in opioid addiction. The methadone withdrawal syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown.
severepersistent painincluding immediate-release opioids
2020
30
METHADONE HYDROCHLORIDE
methadone hydrochloride
Post-LOE
ORAL · CONCENTRATE
mu-agonist; a synthetic opioid with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The methadone withdrawal syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown. Other NMDA receptor antagonists have been shown to produce neurotoxic effects in animals.
1994
30
METHADONE HYDROCHLORIDE
methadone hydrochloride
Post-LOE
ORAL · TABLET, FOR SUSPENSION
mu-agonist; a synthetic opioid with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The methadone withdrawal syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown.
1998
30
METHADONE HYDROCHLORIDE
methadone hydrochloride
Post-LOE
ORAL · SOLUTION
2010
30
MYCOPHENOLATE MOFETIL
mycophenolate mofetil
Post-LOE
ORAL · FOR SUSPENSION
(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. In vitro studies suggest that MPA modulates transcriptional activities in human CD4 T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28. MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stimulation, antibody responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN- Ɣ , IL-17, and TNF-α. Additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Overall, the effect of MPA is cytostatic and reversible.
organ rejectioncombination with other immunosuppressantsorgan rejection in adult+3 more
2019
30
SUCRALFATE
sucralfate oral suspension
Post-LOE
ORAL · SUSPENSION
2022
30
SULFAMETHOXAZOLE AND TRIMETHOPRIM
sulfamethoxazole and trimethoprim
Post-LOE
ORAL · TABLET
Dihydrofolate Reductase Inhibitors
2005
30

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT07009262A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
N/A
N/A
Clinical Trials (1)
NCT07216378Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat
N/A
N/A
Clinical Trials (1)
NCT06628713Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat
N/A
KVD824 Prototype 1 modified-release tablet
Hereditary Angioedema
Phase 1
Clinical Trials (1)
NCT05118958Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations
Phase 1
Phase 1
Clinical Trials (1)
NCT05178355A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT04349800A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers
Phase 1
KVD001 Injection
Diabetic Macular Edema
Phase 1
Clinical Trials (1)
NCT02193113A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
Phase 1
Phase 2
Clinical Trials (1)
NCT04208412A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
Phase 2
Phase 2
Clinical Trials (1)
NCT05055258A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
Phase 2
KVD001 Injection
Diabetic Macular Edema
Phase 2
Clinical Trials (1)
NCT03466099Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
Phase 2
Phase 3
Clinical Trials (1)
NCT05505916An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Phase 3
Phase 3
Clinical Trials (1)
NCT06467084Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
Phase 3
Phase 3
Clinical Trials (1)
NCT05259917A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Phase 3
Phase 3
Clinical Trials (1)
NCT05511922PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 22 approved products, 14 clinical trials
Top TAs: Cardiovascular, Gastroenterology, Hematology
SEC Filings: 2 available
Portfolio Health
Launch1 (5%)
Peak1 (5%)
Post-LOE20 (91%)
22 total products
Therapeutic Area Focus
Cardiovascular
1 marketed
Hematology
1 marketed
Nephrology
1 marketed
Neurology
1 marketed
Psychiatry
1 marketed
Marketed
Pipeline

Financials (FY2025)

Revenue
$50M
R&D Spend
$86M(172%)23%
Net Income
-$127M
Cash
$32M
Source: SEC 10-K Filing